Adiponectin, markers of subclinical inflammation and nerve conduction in individuals with recently diagnosed type 1 and type 2 diabetes

European Journal of Endocrinology

Volumn 174, Issue 4, 2016, Pages 433-443

  Schamarek, Imke ^a,b   Herder, Christian ^a,b   Nowotny, Bettina ^a,b   Carstensen Kirberg, Maren ^a,b   Straßburger, Klaus ^a,b   Nowotny, Peter ^a,b   Strom, Alexander ^a,b   Püttgen, Sonja ^a,b   Müssig, Karsten ^a,b,c   Szendroedi, Julia ^a,b,c   Roden, Michael ^a,b,c   Ziegler, Dan ^a,b,c  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; ADIPOQ PROTEIN, HUMAN; AUTACOID;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GERMANY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; NERVE CONDUCTION VELOCITY TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PERONEUS NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSORIMOTOR NEUROPATHY; SENSORY NERVE CONDUCTION VELOCITY; SUBCLINICAL INFLAMMATION; SURAL NERVE; ULNAR NERVE; AGED; ASYMPTOMATIC DISEASE; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; MIDDLE AGED; MOTONEURON; NERVE CONDUCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADIPONECTIN; ADULT; AGED; ASYMPTOMATIC DISEASES; BIOMARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; GERMANY; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MOTOR NEURONS; NEURAL CONDUCTION; SURAL NERVE; YOUNG ADULT;

EID: 84962535301     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-1010     Document Type: Article

References (47)

1. Zychowska M, Rojewska E, Przewlocka B & Mika J. Mechanisms and pharmacology of diabetic neuropathy-experimental and clinical studies. Pharmacological Reports 2013 65 1601-1610. (doi:10.1016/ S1734-1140(13)71521-4)
2. Jude EB, Abbott CA, Young MJ, Anderson SG, Douglas JT & Boulton AJ. The potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 1998 41 330-336. (doi:10.1007/ s001250050911)
3. Matsuda M, Kawasaki F, Inoue H, Kanda Y, Yamada K, Harada Y, Saito M, Eto M, Matsuki M & Kaku K. Possible contribution of adipocytokines on diabetic neuropathy. Diabetes Research and Clinical Practice 2004 66 S121-S123. (doi:10.1016/j.diabres.2004.05.010)
4. Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T, Döring A, Thorand B, Holle R, Giani G et al. Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany). Diabetes Care 2009 32 680-682. (doi:10.2337/dc08-2011)
5. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T & Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. Journal of Clinical Endocrinology & Metabolism 2009 94 2157-2163. (doi:10.1210/jc.2008-2385)
6. Hussain G, Rizvi SA, Singhal S, Zubair M & Ahmad J. Serum levels of TNF-a in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2013 7 238-242. (doi:10.1016/ j.dsx.2013.02.005)
7. Magrinelli F, Briani C, Romano M, Ruggero S, Toffanin E, Triolo G, Peter GC, Praitano M, Lauriola MF, Zanette G et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. Journal of Diabetes Research 2015 2015 547834. (doi:10.1155/2015/547834)
8. Kallestrup M, Møller HJ, Tankisi H & Andersen H. Soluble CD163 levels are elevated in cerebrospinal fluid and serum in people with type 2 diabetes mellitus and are associated with impaired peripheral nerve function. Diabetic Medicine 2015 32 54-61. (doi:10.1111/dme.12568)
9. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W, Thorand B, Roden M, Meisinger C & Ziegler D. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study. Diabetes Care 2013 36 3663-3670. (doi:10.2337/dc13-0382)
10. Kato K, Osawa H, Ochi M, Kusunoki Y, Ebisui O, Ohno K, Ohashi J, Shimizu I, Fujii Y, Tanimoto M et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clinical Endocrinology 2008 68 442-449. (doi:10.1111/j.1365-2265.2007.03063.x)
11. Jung CH, Kim BY, Mok JO, Kang SK & Kim CH. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 2014 5 333-339. (doi:10.1111/jdi.12144)
12. Pradeepa R, Surendar J, Indulekha K, Chella S, Anjana RM & Mohan V. Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects-(CURES-133). ClinicalBiochemistry 20154833-38. (doi:10.1016/j.clinbiochem.2014.10.009)
13. Turer AT & Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012 55 2319-2326. (doi:10.1007/ s00125-012-2598-x)
14. Ye R & Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Molecular Metabolism 2013 2 133-141. (doi:10.1016/ j.molmet.2013.04.001)
15. Herder C, Carstensen M & Ouwens DM. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obesity & Metabolism 2013 15 (Suppl 3) 39-50. (doi:10.1111/dom.12155)
16. Gonzaélez-Clemente JM, Mauricio D, Richart C, Broch M, Caixàs A, Megia A, Gimeénez-Palop O, Simoén I, Mart?énez-Riquelme A, Gimeénez-Peérez G et al. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clinical Endocrinology 2005 63 525-529. (doi:10.1111/ j.1365-2265.2005.02376.x)
17. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH & EURODIAB Prospective Complications Study Group . Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008 31 1360-1366. (doi:10.2337/dc08-0107)
18. Boulton AJ, Malik RA, Arezzo JC & Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004 27 1458-1486. (doi:10.2337/diacare. 27.6.1458)
19. Dyck PJ, Herrmann DN, Staff NP & Dyck PJ. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes 2013 62 3677-3686. (doi:10.2337/db13-0352)
20. Ziegler D, Behler M, Schroers-Teuber M & Roden M. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open 2015 5 e006559. (doi:10.1136/bmjopen-2014-006559)
21. Ziegler D, Papanas N, Zhivov A, Allgeier S, Winter K, Ziegler I, Brüggemann J, Strom A, Peschel S, Köhler B et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014 63 2454-2463. (doi:10.2337/db13-1819)
22. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metabolism Research & Reviews 2011 27 620-628. (doi:10.1002/dmrr.1226)
23. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L & Boulton AJ. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? Diabetes Care 2002 25 2010-2015. (doi:10.2337/diacare.25.11.2010)
24. Dyck PJ, O'Brien PC, Litchy WJ, Harper CM, Klein CJ & Dyck PJ. Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care 2005 28 2192-2200. (doi:10.2337/diacare.28.9.2192)
25. Weisman A, Bril V, Ngo M, Lovblom LE, Halpern EM, Orszag A & Perkins BA. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS ONE 2013 8 e58783. (doi:10.1371/ journal.pone.0058783)
26. Duksal T, Tiftikcioglu BI, Bilgin S, Kose S & Zorlu Y. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurologica Scandinavica, 2015. In press. (doi:10.1111/ane.12474)
27. Di Iorio A, Cherubini A, Volpato S, Sparvieri E, Lauretani F, Franceschi C, Senin U, Abate G, Paganelli R, Martin A et al. Markers of inflammation, vitamin E and peripheral nervous system function: the InCHIANTI study. Neurobiology of Aging 2006 27 1280-1288. (doi:10.1016/j.neurobiolaging.2005.07.004)
28. Weber KS, Nowotny B, Strassburger K, Pacini G,Müssig K, Szendroedi J, Herder C, Roden M & GDS Group . The role of markers of low-grade inflammation for the early time course of glycemic control, glucose disappearance rate, and b-cell function in recently diagnosed type 1 and type 2 diabetes. Diabetes Care 2015 38 1758-1767. (doi:10.2337/ dc15-0169)
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004 27 (Suppl 1) S5-S10. (doi:10.2337/diacare. 27.2007.S5)
30. Callaghan BC, Hur J & Feldman EL. Diabetic neuropathy: one disease or two? Current Opinion in Neurology 2012 25 536-541. (doi:10.1097/WCO. 0b013e328357a797)
31. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012 379 1214-1224. (doi:10.1016/S0140-6736(12)60110-X)
32. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R & Kadowaki T. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006 29 1357-1362. (doi:10.2337/dc05-1801)
33. Schöttker B, Herder C, Rothenbacher D, Roden M, Kolb H, Müller H & Brenner H. Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study. Diabetes Care 2013 36 1703-1711. (doi:10.2337/dc12-1416)
34. Wu ZJ, Cheng YJ, Gu WJ & Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014 63 1157-1166. (doi:10.1016/j.metabol.2014.05.001)
35. Lieb DC, Parson HK, Mamikunian G & Vinik AI. Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Experimental Diabetes Research 2012 2012 878760. (doi:10.1155/2012/878760)
36. Jung CH, Kim BY, Kim CH, Kang SK, Jung SH & Mok JO. Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients. Cardiovascular Diabetology 2012 11 24. (doi:10.1186/1475-2840-11-24)
37. Rathmann W & Herder C. Adiponectin and cardiovascular mortality: evidence for reverse epidemiology. Hormone and Metabolic Research 2007 39 1-2. (doi:10.1055/s-2007-958630)
38. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, Okazaki H, Asai M, Nagamachi Y, Maeda N et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. Journal of the American College of Cardiology 2009 53 2070-2077. (doi:10.1016/j.jacc.2009.02.038)
39. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, Sayama K, Uno S, Iwahashi H, Yamagata K et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002 25 1665-1666. (doi:10.2337/ diacare.25.9.1665)
40. Leth H, Andersen KK, Frystyk J, Tarnow L, Rossing P, Parving HH & Flyvbjerg A. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. Journal of Clinical Endocrinology & Metabolism 2008 93 3186-3191. (doi:10.1210/jc.2008-0360)
41. Pereira RI, Snell-Bergeon JK, Erickson C, Schauer IE, Bergman BC, Rewers M & Maahs DM. Adiponectin dysregulation and insulin resistance in type 1 diabetes. Journal of Clinical Endocrinology & Metabolism 2012 97 E642-E647. (doi:10.1210/ jc.2011-2542)
42. Saraheimo M, Forsblom C, Thorn L, Wadeén J, Rosengård-Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J, Flyvbjerg A et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008 31 1165-1169. (doi:10.2337/dc07-2306)
43. Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Wadeén J, Gordin D, Frystyk J, Flyvbjerg A, Groop PH et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. Journal of Internal Medicine 2011 270 346-355. (doi:10.1111/j.1365-2796.2011. 02406.x)
44. Cook JR & Semple RK. Hypoadiponectinemia-cause or consequence of human insulin resistance? Journal of Clinical Endocrinology & Metabolism 2010 95 1544-1554. (doi:10.1210/jc.2009-2286)
45. Sattar N. Adiponectin and raised mortality in type 1 diabetes: any credible explanatorymechanisms? Journal of Internal Medicine 2011 270 339-342. (doi:10.1111/j.1365-2796.2011.02408.x)
46. Hwang JY, Park JE, Choi YJ, Huh KB, Chang N & Kim WY. Carbohydrate intake interacts with SNP276GOT polymorphism in the adiponectin gene to affect fasting blood glucose, HbA1C, and HDL cholesterol in Korean patients with type 2 diabetes. Journal of the American College of Nutrition 2013 32 143-150.
47. Ji ZY, Li HF, Lei Y, Rao YW, Tan ZX, Liu HJ, Yao GD, Hou B & Sun ML. Association of adiponectin gene polymorphisms with an elevated risk of diabetic peripheral neuropathy in type 2 diabetes patients. Journal of Diabetes and its Complications 2015 29 887-892. (doi:10.1016/j. jdiacomp.2015.06.008)